HATEM HASSANEIN, M.D.
Medical Oncology Physician in ORLANDO, Florida. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
HATEM HASSANEIN, M.D. filed 698 Medicare Part D claims in 2023 as a Medical Oncology Physician in ORLANDO, Florida, prescribing 59% generic.
- 698
- Part D claims, 2023
- 59%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
HATEM HASSANEIN, M.D.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023 — across all CMS prescribers nationally
698 Top 31% higher than 69% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
HATEM HASSANEIN, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about HATEM HASSANEIN, M.D.?
Quality data not reportedPrimary specialty
Medicare Part D claims
Specialty distribution in Florida
How Medical Oncology Physician compares to other specialties among Florida providers
Medical Oncology Physician share within Florida
Medical Oncology Physician is one of the more visible NUCC categories in Florida
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Specialty board-certification context
Estimated specialty board-certified rate — Medical Oncology Physician (ABMS / AOA reference)
- Est. board-certified rate
- 78%
- Medical Oncology Physician ABMS/AOA estimate
Est. board-certified rate (Medical Oncology Physician) — ABMS / AOA estimate
Verify credentials
- Verify via ABMS free public lookup
- Verify via AOA osteopathic boards
- Specialty volume Medical Oncology Physician US NPIs
Specialty board-certified rate — Medical Oncology Physician estimate
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus Maintenance of Certification cycles. CMS does not publish a per-provider board-certification field; the figure shown is the specialty-level estimated rate from ABMS / AOA reference data.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
HATEM HASSANEIN, M.D. appears in the CMS NPPES registry as a Medical Oncology Physician provider holding M.D. credentials at 1400 S ORANGE AVE, ORLANDO, FL, 32806, with a listed phone of (407) 648-3800. NPI 1639533508 was issued on 04/07/2016. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what HASSANEIN most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 698 prescription claims written by this provider, covering 138 Medicare beneficiaries and totaling roughly $4.1 million in drug spend, split 41% brand-name and 59% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.
Medical Oncology Physician is a narrow specialty nationwide, with 3,792 enrolled providers across 53 states and an average of 689 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1639533508 |
|---|---|
| Specialty | Medical Oncology Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 04/07/2016 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm HATEM HASSANEIN, M.D.'s current license status, disciplinary history, and board certifications with the Florida Board of Medicine in Florida before relying on this page for a clinical or care decision.
How we sourced this profile
Hospital and facility affiliations
Facilities where HATEM HASSANEIN, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
License & disciplinary context — Florida FLDOH 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~75K Florida medical licensees in 2023 — they are NOT specific to HATEM HASSANEIN, M.D.. To verify HATEM HASSANEIN, M.D.'s current license status, search the FLDOH public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
FLDOH publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Florida disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Above average
41% brand-name claims vs 59% generic, on 698 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 756
- Total Day Supply
- 19,518
- Brand vs Generic
- 41% brand / 59% generic
- Brand Drug Cost
- $3.9M
- Generic Drug Cost
- $242K
- Antibiotic Claims
- 16
Patient Demographics
- Average Patient Age
- 73.3 years
- Avg HCC Risk Score
- 2.42
- Gender Split
- 25% female / 75% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What HATEM HASSANEIN, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Prednisone
Prednisone
90 claims
- Abiraterone Acetate
Abiraterone Acetate
89 claims
- Prochlorperazine M…
Prochlorperazine Maleate
59 claims
- Acyclovir
Acyclovir
55 claims
- Revlimid
Revlimid
48 claims
- Eliquis
Eliquis
39 claims
- Xtandi
Xtandi
39 claims
- Nubeqa 26
Nubeqa
26 claims
| Drug | Claims |
|---|---|
| Prednisone | 90 |
| Abiraterone Acetate | 89 |
| Prochlorperazine Maleate | 59 |
| Acyclovir | 55 |
| Revlimid Lenalidomide | 48 |
| Eliquis Apixaban | 39 |
| Xtandi Enzalutamide | 39 |
| Nubeqa Darolutamide | 26 |
| Orgovyx Relugolix | 26 |
| Erleada Apalutamide | 20 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Medical Oncology Physician Overview
How HATEM HASSANEIN, M.D. fits within the Medical Oncology Physician landscape nationally.
HATEM HASSANEIN, M.D.'s 698 claims are above the specialty average of 689.
Nearby Medical Oncology Physician Providers in Florida
Other clinicians with the same primary specialty enrolled in Florida, drawn from the same CMS NPPES roster as HASSANEIN.
Compare Medical Oncology Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Florida
Frequently Asked Questions
What is HATEM HASSANEIN, M.D.'s specialty? ▼
How much does HATEM HASSANEIN, M.D. prescribe under Medicare Part D? ▼
Where is HATEM HASSANEIN, M.D. located? ▼
What is HATEM HASSANEIN, M.D.'s NPI number? ▼
Does HATEM HASSANEIN, M.D. prescribe more brand-name or generic drugs? ▼
How many Medical Oncology Physician providers are there in the US? ▼
What drugs does HATEM HASSANEIN, M.D. prescribe most often? ▼
Does HATEM HASSANEIN, M.D. accept Medicare? ▼
How can I verify HATEM HASSANEIN, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology